DARE News and Press, Dare Bioscience Inc. From 04/03/23

2023-04-03 08:16:44 ET OncoSec Medical ( ONCS ) -62% clinical data of the KEYNOTE-695 trial assessing TAVO EP in combination with KEYTRUDA (pembrolizumab) in patients with advanced melanoma refractory to anti-PD-1 treatment. Ascendis Pharma ( ASND ) -38% after FD...

2023-03-30 23:16:05 ET Dare Bioscience, Inc. (DARE) Q4 2022 Earnings Conference Call March 30, 2023 16:30 ET Company Participants Sabrina Johnson - President & Chief Executive Officer Lisa Walters-Hoffert - Chief Financial Officer John Fair - Chief Strategy O...

2023-03-30 08:31:03 ET Dare Bioscience press release ( NASDAQ: DARE ): FY GAAP EPS of -$0.37 misses by $0.07 . Revenue of $10M in-line. Cash and cash equivalents: $34.7 million at December 31, 2022, compared to $51.7 million at December 31, 2021. Shares +5.77...

Conference Call and Webcast Today at 4:30 p.m. ET 2022 Daré Key Portfolio Accomplishments: License Agreement with Organon to Commercialize XACIATO TM Ovaprene ® IDE Approval for Pivotal Contraceptive Efficacy Study Positive Phase 1/2 Data for both DAR...

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 30, 2023, to review its financial results f...

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will present at the 35 th Annual Roth Conference, being held March...

SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the start of a Phase 1 study evaluating its development program targeted at treating primary dysmenorrhea by delivering the active pharmaceutical i...

SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in the following February conferences: 2023 BI...

Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO,...

The women’s health company Daré Bioscience ( NASDAQ: DARE ) added ~13% on Wednesday to reach the highest level since June 2022 after announcing that its shares have regained Nasdaq compliance for continued listing. According to a Nasdaq communication on Jan. 24, Dar&#x...